2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003
December 6, 2010
Ascenta Therapeutics and The Leukemia & Lymphoma Society Announce Agreement to Develop AT-406 for Leukemia
December 1, 2010
Ascenta Therapeutics and Ascentage Pharma Sign R&D Collaboration and Regional License Agreements for Two Cancer Programs
June 4, 2010
Ascenta Therapeutics Licenses
Cancer Drug Candidates to Sanofi-Aventis
October 26, 2009
Ascenta Therapeutics Announces Presentation of Results from a Dose-Ranging Study of AT-101 with Standard Therapy in Patients with Glioblastoma Multiforme
September 10, 2009
Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials with AT-406
May 26th, 2009:
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at the 2009 ASCO Annual Meeting
February 27, 2009
Ascenta Therapeutics Presents New Clinical Data on AT-101 for the Treatment of Hormone-Refractory Prostate Cancer
April 11, 2008
Ascenta Therapeutics Highlights Multiple Data Presentations at AACR 2008 Conference
October 23, 2007
Ascenta Therapeutics Highlights Multiple Data Presentations at this week’s AACR-NCI-EORTC International Conference in San Francisco
August 24, 2007
Ascenta Therapeutics Presents New Clinical Data on AT-101 for the Treatment of Hormone-Refractory Prostate Cancer
June 6, 2007
FierceBiotech Names Ascenta Therapeutics as One of the “Fierce 15" Biotech Companies of 2007
April 13, 2007
Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting
April 9, 2007
Ascenta Therapeutics Raises $50 Million in Series C Financing
February 23, 2007
Ascenta Therapeutics Presents New Clinical Data on AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer
December 10, 2006
Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia
Ascenta Therapeutics Presents New Preclinical Data on Mdm2 Inhibitor Portfolio Compound MI-63
October 27, 2006
Ascenta Ascending - A Model of Efficiency in Drug Development - Company Profiled in the San Diego Union Tribune
September 18, 2006
Ascenta Appointment of Craig Kussman, MBA, as Chief Financial Officer of Ascenta Therapeutics
July, 2006
Ascenta Profiled in July/August Edition of Windhover's Start Up Magazine
June 7, 2006
Ascenta's Oral Pan-Bcl-2 Inhibitor Ranked in Top Ten Leading Cancer Projects by Windhover Information, Inc.
Apr 11, 2006
Ascenta Therapeutics Hosts Shanghai Delegation During Visit to San Diego, California
Mel Sorensen, MD of Ascenta Therapeutics, Speaks at BIO 2006 in Chicago
April 4, 2006
Ascenta Therapeutics Novel MDM2-p53 Inhibitors Demonstrate Preclinical Single Agent Efficacy in Multiple Tumor Models
February 1, 2006
Appointment of Lance Leopold, M.D., as Vice-President of Clinical Development
December 12, 2005
Ascenta AT-101 Data Presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta, Georgia
Preclinical Data on Ascenta Therapeutics Pipeline Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania
November 10, 2005
Phase II Program of Ascenta's Lead Product, AT-101, a Pan-inhibitor of the Bcl-2 Protein Family, Begins
September 29, 2005
Mel Sorensen, MD of Ascenta Therapeutics, Speaks at the Moores Cancer Center Symposium
September 21, 2005
Ascenta Therapeutics Opens an R&D Center in Shanghai's High-Tech Park in Pu-Dong, China
July 7, 2005
Ascenta Therapeutics Moves to New Offices in San Diego, California
June 1, 2005
Appointment of Three New Vice-Presidents to the Executive Team at Ascenta Therapeutics
April 27, 2005
Ascenta Therapeutics Leaders Participate in Shanghai's Bio-Forum Conference
April 18, 2005
Mel Sorensen, MD of Ascenta Therapeutics, Speaks at the Milken Institute's Global Conference in Los Angeles
April 5, 2005
Mel Sorensen, MD, President and CEO of Ascenta Therapeutics, Speaks at Tokyo's Pharma Partnering Conference
January 31, 2005
First Patient Entered onto Ascenta Therapeutics' Phase I Trial of its Lead Product, AT-101, a Pan-inhibitor of the Bcl-2 Protein Family
November 05, 2004
Ascenta raises Series B Financing of $30 Million, with Bank of America, Sofinnova, Domain, Enterprise and US-Venture Partners
August 16, 2004
Appointment of J. Mel Sorensen, M.D., as President and Chief Executive Officer of Ascenta Therapeutics
April 12, 2004
Appointment of Jon Holmlund, M.D., as Chief Medical Officer and Vice-President of Development to Ascenta Therapeutics
March 1, 2004
Appointment of Dajun Yang, M.D., Ph.D., as Vice-President of Research of Ascenta Therapeutics
December 05, 2003
Series A Financing of $5.5 Million with Sofinnova Ventures, Domain Associates and Enterprise Partners Venture Capital
